Compile Data Set for Download or QSAR

Found 966 hits of ic50 for UniProtKB: P00747   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Plasminogen (Homo sapiens (Human))	BDBM50120225 (2-{[2-(4-Guanidino-butyrylamino)-3-(4-nitro-phenyl...) Show SMILES CC(O)C(N(C)C(=O)C(Cc1ccc(cc1)[N+]([O-])=O)NC(=O)CCC[N-]C(N)=[NH2+])C(=O)NC(C)c1ccccc1 Show InChI InChI=1S/C27H37N7O6/c1-17(20-8-5-4-6-9-20)31-25(37)24(18(2)35)33(3)26(38)22(32-23(36)10-7-15-30-27(28)29)16-19-11-13-21(14-12-19)34(39)40/h4-6,8-9,11-14,17-18,22,24,35H,7,10,15-16H2,1-3H3,(H6,28,29,30,31,32,36,37)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	n/a	n/a	0.230	n/a	n/a	n/a	n/a	n/a	n/a
Bristol-Myers Squibb Pharmaceutical Research Institute Curated by ChEMBL					Assay Description Concentration of the compound required to inhibit Plasmin was determined				Bioorg Med Chem Lett 12: 3183-6 (2002) BindingDB Entry DOI: 10.7270/Q20P0ZBK
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM50514073 (CHEMBL4576519) Show SMILES CC(C)NC(=O)c1ccc(c(C)c1)-c1ccc(C[C@H](NC(=O)[C@H]2CC[C@H](CN)CC2)C(=O)Nc2cc(Cl)c3cn[nH]c3c2)cc1 |r,wU:25.26,wD:22.22,18.18,(23.11,-16.8,;23.1,-15.26,;24.43,-14.49,;21.77,-14.5,;20.43,-15.27,;20.44,-16.81,;19.1,-14.5,;17.76,-15.28,;16.43,-14.51,;16.43,-12.97,;17.76,-12.19,;17.75,-10.65,;19.09,-12.96,;15.1,-12.2,;13.76,-12.97,;12.43,-12.2,;12.44,-10.66,;11.11,-9.89,;11.11,-8.35,;9.77,-7.58,;8.44,-8.35,;7.1,-7.58,;8.44,-9.89,;7.11,-10.66,;7.11,-12.2,;8.44,-12.97,;8.44,-14.51,;7.1,-15.28,;9.77,-12.2,;9.77,-10.66,;12.44,-7.58,;12.44,-6.04,;13.77,-8.35,;15.11,-7.58,;15.1,-6.05,;16.43,-5.27,;16.42,-3.73,;17.77,-6.04,;19.23,-5.58,;20.13,-6.82,;19.22,-8.06,;17.76,-7.58,;16.44,-8.35,;13.76,-9.89,;15.09,-10.65,)| Show InChI InChI=1S/C35H41ClN6O3/c1-20(2)39-34(44)26-12-13-28(21(3)14-26)24-8-4-22(5-9-24)15-32(41-33(43)25-10-6-23(18-37)7-11-25)35(45)40-27-16-30(36)29-19-38-42-31(29)17-27/h4-5,8-9,12-14,16-17,19-20,23,25,32H,6-7,10-11,15,18,37H2,1-3H3,(H,38,42)(H,39,44)(H,40,45)(H,41,43)/t23-,25-,32-/m0/s1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.320	n/a	n/a	n/a	n/a	n/a	n/a
Philipps University Marburg Curated by ChEMBL					Assay Description Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...				J Med Chem 63: 1445-1472 (2020) Article DOI: 10.1021/acs.jmedchem.9b01060 BindingDB Entry DOI: 10.7270/Q2VQ361P
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM50514076 (CHEMBL4456691) Show SMILES Cc1cc2[nH]c(nc2cc1-c1ccc(C[C@H](NC(=O)[C@H]2CC[C@H](CN)CC2)C(=O)Nc2cc(Cl)c3[nH]c(=O)[nH]c3c2)cc1)C1CC1 |r,wU:22.24,wD:19.20,15.16,(35.34,-31.42,;36.67,-30.65,;38,-31.42,;39.34,-30.65,;40.81,-31.11,;41.71,-29.85,;40.79,-28.61,;39.33,-29.1,;38,-28.34,;36.67,-29.11,;35.34,-28.34,;34,-29.11,;32.67,-28.34,;32.68,-26.8,;31.34,-26.03,;31.34,-24.49,;30.01,-23.72,;28.68,-24.49,;27.34,-23.72,;28.68,-26.03,;27.35,-26.81,;27.35,-28.35,;28.68,-29.11,;28.68,-30.65,;27.34,-31.42,;30,-28.35,;30,-26.81,;32.68,-23.72,;32.68,-22.18,;34.01,-24.49,;35.34,-23.72,;35.34,-22.19,;36.67,-21.42,;36.66,-19.88,;38.01,-22.18,;39.48,-21.71,;40.38,-22.96,;41.92,-22.97,;39.47,-24.21,;38,-23.72,;36.68,-24.5,;34,-26.03,;35.33,-26.8,;43.25,-29.83,;44.59,-30.59,;44.57,-29.05,)| Show InChI InChI=1S/C35H38ClN7O3/c1-18-12-27-28(40-32(39-27)22-10-11-22)16-25(18)21-6-2-19(3-7-21)13-30(41-33(44)23-8-4-20(17-37)5-9-23)34(45)38-24-14-26(36)31-29(15-24)42-35(46)43-31/h2-3,6-7,12,14-16,20,22-23,30H,4-5,8-11,13,17,37H2,1H3,(H,38,45)(H,39,40)(H,41,44)(H2,42,43,46)/t20-,23-,30-/m0/s1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	n/a
Philipps University Marburg Curated by ChEMBL					Assay Description Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...				J Med Chem 63: 1445-1472 (2020) Article DOI: 10.1021/acs.jmedchem.9b01060 BindingDB Entry DOI: 10.7270/Q2VQ361P
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM50514062 (CHEMBL4436082) Show SMILES Cc1nc2[nH]c(nc2cc1-c1ccc(C[C@H](NC(=O)[C@H]2CC[C@H](CN)CC2)C(=O)Nc2cc(Cl)c3[nH]c(=O)[nH]c3c2)cc1)C1CC1 |r,wU:22.24,wD:19.20,15.16,(55.88,-32.78,;57.22,-32.01,;58.55,-32.78,;59.89,-32,;61.36,-32.46,;62.26,-31.21,;61.34,-29.97,;59.88,-30.46,;58.54,-29.69,;57.22,-30.47,;55.89,-29.7,;54.55,-30.47,;53.22,-29.7,;53.23,-28.16,;51.89,-27.39,;51.89,-25.85,;50.56,-25.08,;49.23,-25.85,;47.89,-25.08,;49.23,-27.39,;47.9,-28.16,;47.9,-29.7,;49.23,-30.47,;49.23,-32.01,;47.89,-32.78,;50.55,-29.7,;50.55,-28.16,;53.23,-25.08,;53.23,-23.54,;54.56,-25.85,;55.89,-25.08,;55.89,-23.55,;57.22,-22.77,;57.21,-21.23,;58.56,-23.53,;60.03,-23.06,;60.93,-24.32,;62.47,-24.32,;60.02,-25.56,;58.55,-25.08,;57.23,-25.85,;54.55,-27.39,;55.88,-28.15,;63.8,-31.19,;65.14,-31.94,;65.12,-30.4,)| Show InChI InChI=1S/C34H37ClN8O3/c1-17-24(15-27-31(37-17)43-30(39-27)21-10-11-21)20-6-2-18(3-7-20)12-28(40-32(44)22-8-4-19(16-36)5-9-22)33(45)38-23-13-25(35)29-26(14-23)41-34(46)42-29/h2-3,6-7,13-15,19,21-22,28H,4-5,8-12,16,36H2,1H3,(H,38,45)(H,40,44)(H,37,39,43)(H2,41,42,46)/t19-,22-,28-/m0/s1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	n/a
Philipps University Marburg Curated by ChEMBL					Assay Description Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...				J Med Chem 63: 1445-1472 (2020) Article DOI: 10.1021/acs.jmedchem.9b01060 BindingDB Entry DOI: 10.7270/Q2VQ361P
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM50514063 (CHEMBL4447001) Show SMILES CC(C)c1nc2nc(C)c(cc2[nH]1)-c1ccc(C[C@H](NC(=O)[C@H]2CC[C@H](CN)CC2)C(=O)Nc2ccc(cc2)-c2nnc([nH]2)C(F)(F)C(F)(F)C(O)=O)cc1 |r,wU:25.27,wD:22.23,18.19,(16.63,-38.54,;17.41,-37.21,;18.95,-37.23,;16.65,-35.87,;17.29,-34.47,;16.15,-33.42,;16.14,-31.87,;14.8,-31.11,;14.8,-29.57,;13.48,-31.88,;13.48,-33.42,;14.8,-34.18,;15.11,-35.7,;12.14,-31.11,;10.81,-31.88,;9.48,-31.11,;9.48,-29.57,;8.14,-28.8,;8.14,-27.26,;6.82,-26.49,;5.48,-27.26,;4.15,-26.49,;5.48,-28.8,;4.15,-29.58,;4.15,-31.12,;5.48,-31.88,;5.48,-33.42,;4.15,-34.19,;6.81,-31.12,;6.81,-29.58,;9.48,-26.49,;9.48,-24.95,;10.82,-27.26,;12.15,-26.49,;13.48,-27.27,;14.81,-26.49,;14.82,-24.95,;13.47,-24.19,;12.15,-24.96,;16.14,-24.18,;16.3,-22.65,;17.81,-22.33,;18.58,-23.66,;17.55,-24.8,;20.12,-23.65,;20.9,-24.98,;19.34,-24.98,;20.88,-22.31,;20.11,-20.98,;21.65,-20.98,;22.42,-22.31,;23.2,-23.64,;23.19,-20.97,;10.81,-28.8,;12.14,-29.56,)| Show InChI InChI=1S/C38H41F4N9O4/c1-19(2)30-46-28-17-27(20(3)44-32(28)48-30)23-8-4-21(5-9-23)16-29(47-33(52)25-10-6-22(18-43)7-11-25)34(53)45-26-14-12-24(13-15-26)31-49-35(51-50-31)37(39,40)38(41,42)36(54)55/h4-5,8-9,12-15,17,19,22,25,29H,6-7,10-11,16,18,43H2,1-3H3,(H,45,53)(H,47,52)(H,54,55)(H,44,46,48)(H,49,50,51)/t22-,25-,29-/m0/s1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.420	n/a	n/a	n/a	n/a	n/a	n/a
Philipps University Marburg Curated by ChEMBL					Assay Description Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...				J Med Chem 63: 1445-1472 (2020) Article DOI: 10.1021/acs.jmedchem.9b01060 BindingDB Entry DOI: 10.7270/Q2VQ361P
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM50514065 (CHEMBL4570952) Show SMILES CC(C)NC(=O)c1ccc(c(C)n1)-c1ccc(C[C@H](NC(=O)[C@H]2CC[C@H](CN)CC2)C(=O)Nc2cc(Cl)c3oc(=O)[nH]c3c2)cc1 |r,wU:25.26,wD:22.22,18.18,(44.05,-15.78,;44.05,-14.24,;45.38,-13.46,;42.71,-13.47,;41.38,-14.24,;41.38,-15.78,;40.04,-13.48,;38.71,-14.25,;37.38,-13.48,;37.38,-11.94,;38.7,-11.17,;38.7,-9.63,;40.04,-11.93,;36.04,-11.17,;34.71,-11.94,;33.38,-11.17,;33.38,-9.63,;32.05,-8.86,;32.05,-7.32,;30.72,-6.55,;29.38,-7.32,;28.05,-6.55,;29.38,-8.86,;28.05,-9.64,;28.05,-11.18,;29.38,-11.94,;29.38,-13.48,;28.05,-14.25,;30.71,-11.18,;30.71,-9.64,;33.38,-6.55,;33.38,-5.01,;34.72,-7.32,;36.05,-6.55,;36.05,-5.02,;37.37,-4.25,;37.37,-2.71,;38.72,-5.01,;40.19,-4.54,;41.09,-5.79,;42.63,-5.8,;40.17,-7.03,;38.71,-6.55,;37.38,-7.33,;34.71,-8.86,;36.04,-9.62,)| Show InChI InChI=1S/C34H39ClN6O5/c1-18(2)37-32(43)27-13-12-25(19(3)38-27)22-8-4-20(5-9-22)14-29(40-31(42)23-10-6-21(17-36)7-11-23)33(44)39-24-15-26(35)30-28(16-24)41-34(45)46-30/h4-5,8-9,12-13,15-16,18,21,23,29H,6-7,10-11,14,17,36H2,1-3H3,(H,37,43)(H,39,44)(H,40,42)(H,41,45)/t21-,23-,29-/m0/s1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.800	n/a	n/a	n/a	n/a	n/a	n/a
Philipps University Marburg Curated by ChEMBL					Assay Description Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...				J Med Chem 63: 1445-1472 (2020) Article DOI: 10.1021/acs.jmedchem.9b01060 BindingDB Entry DOI: 10.7270/Q2VQ361P
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM50514079 (CHEMBL4449958) Show SMILES CC(C)c1nc2cc(C)c(cc2[nH]1)-c1ccc(C[C@H](NC(=O)[C@H]2CC[C@H](CN)CC2)C(=O)Nc2ccc(cc2)-c2nnc([nH]2)C(F)(F)C(F)(F)C(O)=O)cc1 |r,wU:25.27,wD:22.23,18.19,(59.05,-21.3,;59.83,-19.97,;61.37,-19.99,;59.08,-18.63,;59.72,-17.22,;58.58,-16.18,;58.56,-14.63,;57.23,-13.87,;57.22,-12.33,;55.9,-14.64,;55.9,-16.18,;57.23,-16.94,;57.54,-18.46,;54.57,-13.87,;53.24,-14.64,;51.9,-13.87,;51.91,-12.33,;50.57,-11.56,;50.57,-10.02,;49.24,-9.25,;47.91,-10.02,;46.58,-9.25,;47.91,-11.56,;46.58,-12.34,;46.58,-13.88,;47.91,-14.64,;47.91,-16.18,;46.58,-16.95,;49.24,-13.88,;49.24,-12.34,;51.91,-9.25,;51.91,-7.71,;53.24,-10.02,;54.58,-9.25,;55.91,-10.02,;57.23,-9.25,;57.24,-7.71,;55.9,-6.94,;54.57,-7.72,;58.57,-6.94,;58.73,-5.41,;60.24,-5.08,;61.01,-6.42,;59.98,-7.56,;62.55,-6.41,;63.32,-7.74,;61.77,-7.74,;63.31,-5.07,;62.54,-3.74,;64.07,-3.73,;64.85,-5.06,;65.63,-6.39,;65.62,-3.73,;53.23,-11.56,;54.57,-12.32,)| Show InChI InChI=1S/C39H42F4N8O4/c1-20(2)32-46-29-16-21(3)28(18-30(29)47-32)24-8-4-22(5-9-24)17-31(48-34(52)26-10-6-23(19-44)7-11-26)35(53)45-27-14-12-25(13-15-27)33-49-36(51-50-33)38(40,41)39(42,43)37(54)55/h4-5,8-9,12-16,18,20,23,26,31H,6-7,10-11,17,19,44H2,1-3H3,(H,45,53)(H,46,47)(H,48,52)(H,54,55)(H,49,50,51)/t23-,26-,31-/m0/s1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.870	n/a	n/a	n/a	n/a	n/a	n/a
Philipps University Marburg Curated by ChEMBL					Assay Description Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...				J Med Chem 63: 1445-1472 (2020) Article DOI: 10.1021/acs.jmedchem.9b01060 BindingDB Entry DOI: 10.7270/Q2VQ361P
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM50514077 (CHEMBL4475211) Show SMILES CNC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(cc2)-c2cc3[nH]cc(C(O)=O)c(=O)c3cc2C)NC(=O)[C@H]2CC[C@H](CN)CC2)cc1Cl |r,wU:40.43,wD:37.39,11.11,(20.68,-5.12,;19.35,-5.89,;18.02,-5.13,;18.02,-3.59,;16.68,-5.9,;16.68,-7.44,;15.35,-8.22,;14.02,-7.44,;12.68,-8.21,;11.35,-7.44,;11.35,-5.9,;10.01,-8.21,;10.01,-9.75,;11.35,-10.52,;11.34,-12.06,;12.67,-12.83,;14.01,-12.06,;14,-10.51,;12.67,-9.75,;15.34,-12.83,;15.34,-14.37,;16.67,-15.13,;16.67,-16.66,;18,-17.45,;19.33,-16.68,;20.66,-17.46,;22,-16.69,;20.65,-19,;19.35,-15.13,;20.67,-14.37,;18.01,-14.37,;18.01,-12.82,;16.67,-12.06,;16.66,-10.52,;8.69,-7.44,;7.35,-8.21,;6.02,-7.44,;7.35,-9.75,;6.02,-10.52,;6.02,-12.06,;7.35,-12.83,;7.35,-14.37,;6.02,-15.14,;8.68,-12.06,;8.68,-10.52,;14.01,-5.91,;15.34,-5.14,;15.34,-3.6,)| Show InChI InChI=1S/C36H38ClN5O6/c1-19-13-27-30(40-18-28(32(27)43)36(47)48)16-26(19)22-7-3-20(4-8-22)14-31(42-33(44)23-9-5-21(17-38)6-10-23)35(46)41-24-11-12-25(29(37)15-24)34(45)39-2/h3-4,7-8,11-13,15-16,18,21,23,31H,5-6,9-10,14,17,38H2,1-2H3,(H,39,45)(H,40,43)(H,41,46)(H,42,44)(H,47,48)/t21-,23-,31-/m0/s1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	1	n/a	n/a	n/a	n/a	n/a	n/a
Philipps University Marburg Curated by ChEMBL					Assay Description Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...				J Med Chem 63: 1445-1472 (2020) Article DOI: 10.1021/acs.jmedchem.9b01060 BindingDB Entry DOI: 10.7270/Q2VQ361P
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM50514078 (CHEMBL4582882) Show SMILES Cc1cc2c(cc1-c1ccc(C[C@H](NC(=O)[C@H]3CC[C@H](CN)CC3)C(=O)Nc3cc(Cl)c4[nH]c(=O)[nH]c4c3)cc1)[nH]cc(C(O)=O)c2=O |r,wU:19.20,wD:16.16,12.12,(35.27,-11.33,;35.27,-12.87,;36.61,-13.63,;36.61,-15.18,;35.28,-15.94,;33.95,-15.18,;33.95,-13.64,;32.61,-12.87,;31.28,-13.64,;29.95,-12.87,;29.95,-11.33,;28.61,-10.56,;28.61,-9.02,;27.29,-8.25,;25.95,-9.02,;24.62,-8.25,;25.95,-10.56,;24.62,-11.34,;24.62,-12.88,;25.95,-13.64,;25.95,-15.18,;24.62,-15.95,;27.28,-12.88,;27.28,-11.34,;29.95,-8.25,;29.95,-6.71,;31.29,-9.02,;32.62,-8.25,;32.62,-6.72,;33.94,-5.95,;33.94,-4.41,;35.28,-6.7,;36.76,-6.23,;37.67,-7.49,;39.21,-7.49,;36.75,-8.74,;35.28,-8.25,;33.95,-9.03,;31.28,-10.56,;32.61,-11.33,;35.27,-17.48,;36.6,-18.26,;37.94,-17.49,;39.26,-18.27,;40.6,-17.51,;39.26,-19.81,;37.95,-15.95,;39.28,-15.18,)| Show InChI InChI=1S/C35H35ClN6O6/c1-17-10-24-27(38-16-25(31(24)43)34(46)47)14-23(17)20-6-2-18(3-7-20)11-29(40-32(44)21-8-4-19(15-37)5-9-21)33(45)39-22-12-26(36)30-28(13-22)41-35(48)42-30/h2-3,6-7,10,12-14,16,19,21,29H,4-5,8-9,11,15,37H2,1H3,(H,38,43)(H,39,45)(H,40,44)(H,46,47)(H2,41,42,48)/t19-,21-,29-/m0/s1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	2.10	n/a	n/a	n/a	n/a	n/a	n/a
Philipps University Marburg Curated by ChEMBL					Assay Description Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...				J Med Chem 63: 1445-1472 (2020) Article DOI: 10.1021/acs.jmedchem.9b01060 BindingDB Entry DOI: 10.7270/Q2VQ361P
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM652813 (3-chloro-N-((2-((1-methylpiperidin-4-yl)methoxy)py...) Show SMILES Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	UniChem		n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM652497 (N-((6-(((1-methylpiperidin-4-yl)methyl)amino)pyrid...) Show SMILES Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	UniChem		n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM652723 ((S*)-4-chloro-N6-((2-((5,6,7,8-tetrahydroimidazo[1...) Show SMILES Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	UniChem		n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM652421 (6-N-({6-[(1-methylpiperidin-4-yl)oxy]pyridin-3-yl}...) Show SMILES Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	UniChem		n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM652422 (5-N-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}methyl...) Show SMILES Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	UniChem		n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM652473 (5-N-[(6-{5H,6H,8H-imidazo[1,2-a]piperazin-7-yl}pyr...) Show SMILES Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	UniChem		n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM652731 ((S*)-N5-((2-((2-methyl-5,6,7,8-tetrahydroimidazo[1...) Show SMILES Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	UniChem		n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM652632 (5-N-[(2-fluoro-4-{2-[(15,4S)-5-isopropyl-2,5-diaza...) Show SMILES Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	UniChem		n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM652645 (N6-((2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)m...) Show SMILES Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	UniChem		n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM652648 (N-({2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-y...) Show SMILES Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	UniChem		n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM652654 (4-chloro-6-N-({2-[(1-methylpiperidin-4-yl)methoxy]...) Show SMILES Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	UniChem		n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM652657 (6-N-({2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4...) Show SMILES Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	UniChem		n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM652689 (4-fluoro-5-N-[(2-{5H,6H,7H,8H-imidazo[1,2-a]pyridi...) Show SMILES Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	UniChem		n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM652722 (4-chloro-6-N-[(2-{5H,6H,8H-imidazo[1,2-a]pyrazin-7...) Show SMILES Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	UniChem		n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM50514075 (CHEMBL4541084) Show SMILES CCOC(=O)c1ccc(c(C)n1)-c1ccc(C[C@H](NC(=O)[C@H]2CC[C@H](CN)CC2)C(=O)Nc2ccc(cc2)-c2nn[nH]n2)cc1 |r,wU:24.25,wD:21.21,17.17,(24.34,-30.13,;23.01,-30.9,;21.67,-30.14,;20.34,-30.91,;20.35,-32.45,;19.01,-30.15,;17.67,-30.92,;16.34,-30.15,;16.34,-28.61,;17.66,-27.84,;17.66,-26.3,;19,-28.6,;15.01,-27.84,;13.67,-28.61,;12.34,-27.84,;12.35,-26.3,;11.01,-25.53,;11.01,-23.99,;9.68,-23.22,;8.34,-23.99,;7.01,-23.22,;8.34,-25.53,;7.02,-26.3,;7.02,-27.84,;8.34,-28.61,;8.34,-30.15,;7.01,-30.92,;9.67,-27.84,;9.67,-26.3,;12.35,-23.22,;12.35,-21.68,;13.68,-23.99,;15.01,-23.22,;16.34,-23.99,;17.67,-23.22,;17.68,-21.68,;16.34,-20.91,;15.01,-21.69,;19.01,-20.9,;20.42,-21.52,;21.45,-20.38,;20.68,-19.04,;19.17,-19.37,;13.67,-25.53,;15,-26.29,)| Show InChI InChI=1S/C33H38N8O4/c1-3-45-33(44)28-17-16-27(20(2)35-28)23-8-4-21(5-9-23)18-29(37-31(42)25-10-6-22(19-34)7-11-25)32(43)36-26-14-12-24(13-15-26)30-38-40-41-39-30/h4-5,8-9,12-17,22,25,29H,3,6-7,10-11,18-19,34H2,1-2H3,(H,36,43)(H,37,42)(H,38,39,40,41)/t22-,25-,29-/m0/s1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	8.60	n/a	n/a	n/a	n/a	n/a	n/a
Philipps University Marburg Curated by ChEMBL					Assay Description Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...				J Med Chem 63: 1445-1472 (2020) Article DOI: 10.1021/acs.jmedchem.9b01060 BindingDB Entry DOI: 10.7270/Q2VQ361P
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM50029498 (1N-[2-{2-[4-amino(imino)methylamino-1-formyl-(1S)-...) Show SMILES [#6][C@]([#7]-[#6](=O)C(F)(F)F)([#6](=O)-[#7]-1-[#6]-[#6]-[#6@H]-1-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#6]=O)c1ccccc1 Show InChI InChI=1S/C21H27F3N6O4/c1-20(13-6-3-2-4-7-13,29-17(33)21(22,23)24)18(34)30-11-9-15(30)16(32)28-14(12-31)8-5-10-27-19(25)26/h2-4,6-7,12,14-15H,5,8-11H2,1H3,(H,28,32)(H,29,33)(H4,25,26,27)/t14-,15-,20+/m0/s1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	n/a	n/a	9.60	n/a	n/a	n/a	n/a	n/a	n/a
Lilly Research Laboratories Curated by ChEMBL					Assay Description In vitro Enzyme Inhibitory activity measured against Plasmin				J Med Chem 38: 4446-53 (1995) BindingDB Entry DOI: 10.7270/Q2RB73MV
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM50591422 (CHEMBL5175689) Show SMILES NC(=N)c1ccc(CNC(=O)c2cnn(Cc3ccccc3)c2)cc1 Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem		n/a	n/a	>10	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290292 (2-Oxo-4-(piperidin-4-yl)-1,2-dihydropyrimido[1,2-b...) Show SMILES O=c1cc(C2CCNCC2)n2nc3cccc(C#N)c3c2[nH]1 Show InChI InChI=1S/C16H15N5O/c17-9-11-2-1-3-12-15(11)16-19-14(22)8-13(21(16)20-12)10-4-6-18-7-5-10/h1-3,8,10,18H,4-7H2,(H,19,22)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	10	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM50124990 (CHEMBL355376 | N-[4-Guanidino-1-(thiazole-2-carbon...) Show SMILES NC(=N)NCCCC(NC(=O)CN1CCN(CC1=O)S(=O)(=O)c1cccc2cccnc12)C(=O)c1nccs1 Show InChI InChI=1S/C24H28N8O5S2/c25-24(26)29-9-3-6-17(22(35)23-28-10-13-38-23)30-19(33)14-31-11-12-32(15-20(31)34)39(36,37)18-7-1-4-16-5-2-8-27-21(16)18/h1-2,4-5,7-8,10,13,17H,3,6,9,11-12,14-15H2,(H,30,33)(H4,25,26,29)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	n/a	n/a	10	n/a	n/a	n/a	n/a	n/a	n/a
Millennium Pharmaceuticals Inc. Curated by ChEMBL					Assay Description Inhibitory activity against Plasmin				Bioorg Med Chem Lett 13: 723-8 (2003) BindingDB Entry DOI: 10.7270/Q2Z037JH
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290292 (2-Oxo-4-(piperidin-4-yl)-1,2-dihydropyrimido[1,2-b...) Show SMILES O=c1cc(C2CCNCC2)n2nc3cccc(C#N)c3c2[nH]1 Show InChI InChI=1S/C16H15N5O/c17-9-11-2-1-3-12-15(11)16-19-14(22)8-13(21(16)20-12)10-4-6-18-7-5-10/h1-3,8,10,18H,4-7H2,(H,19,22)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	10	n/a	n/a	n/a	n/a	7.0	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...				US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290336 (10-Chloro-8-methyl-4-(piperidin-4-yl)pyrimido[1,2-...) Show SMILES Cc1cc(Cl)c2c(c1)nn1c(cc(=O)[nH]c21)C1CCNCC1 Show InChI InChI=1S/C16H17ClN4O/c1-9-6-11(17)15-12(7-9)20-21-13(8-14(22)19-16(15)21)10-2-4-18-5-3-10/h6-8,10,18H,2-5H2,1H3,(H,19,22)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11	n/a	n/a	n/a	n/a	7.0	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...				US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290336 (10-Chloro-8-methyl-4-(piperidin-4-yl)pyrimido[1,2-...) Show SMILES Cc1cc(Cl)c2c(c1)nn1c(cc(=O)[nH]c21)C1CCNCC1 Show InChI InChI=1S/C16H17ClN4O/c1-9-6-11(17)15-12(7-9)20-21-13(8-14(22)19-16(15)21)10-2-4-18-5-3-10/h6-8,10,18H,2-5H2,1H3,(H,19,22)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290334 (9-Fluoro-10-phenyl-4-(piperidin-4-yl)pyrimido[1,2-...) Show SMILES Fc1ccc2nn3c(cc(=O)[nH]c3c2c1-c1ccccc1)C1CCNCC1 Show InChI InChI=1S/C21H19FN4O/c22-15-6-7-16-20(19(15)14-4-2-1-3-5-14)21-24-18(27)12-17(26(21)25-16)13-8-10-23-11-9-13/h1-7,12-13,23H,8-11H2,(H,24,27)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290334 (9-Fluoro-10-phenyl-4-(piperidin-4-yl)pyrimido[1,2-...) Show SMILES Fc1ccc2nn3c(cc(=O)[nH]c3c2c1-c1ccccc1)C1CCNCC1 Show InChI InChI=1S/C21H19FN4O/c22-15-6-7-16-20(19(15)14-4-2-1-3-5-14)21-24-18(27)12-17(26(21)25-16)13-8-10-23-11-9-13/h1-7,12-13,23H,8-11H2,(H,24,27)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11	n/a	n/a	n/a	n/a	7.0	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...				US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290324 (4-(Piperidin-4-yl)-10-[2-(trifluoromethyl)phenyl]p...) Show SMILES FC(F)(F)c1ccccc1-c1cccc2nn3c(cc(=O)[nH]c3c12)C1CCNCC1 Show InChI InChI=1S/C22H19F3N4O/c23-22(24,25)16-6-2-1-4-14(16)15-5-3-7-17-20(15)21-27-19(30)12-18(29(21)28-17)13-8-10-26-11-9-13/h1-7,12-13,26H,8-11H2,(H,27,30)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290314 (10-(2-Fluorophenyl)-4-(piperidin-4-yl)pyrimido[1,2...) Show SMILES Fc1ccccc1-c1cccc2nn3c(cc(=O)[nH]c3c12)C1CCNCC1 Show InChI InChI=1S/C21H19FN4O/c22-16-6-2-1-4-14(16)15-5-3-7-17-20(15)21-24-19(27)12-18(26(21)25-17)13-8-10-23-11-9-13/h1-7,12-13,23H,8-11H2,(H,24,27)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13	n/a	n/a	n/a	n/a	7.0	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...				US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290314 (10-(2-Fluorophenyl)-4-(piperidin-4-yl)pyrimido[1,2...) Show SMILES Fc1ccccc1-c1cccc2nn3c(cc(=O)[nH]c3c12)C1CCNCC1 Show InChI InChI=1S/C21H19FN4O/c22-16-6-2-1-4-14(16)15-5-3-7-17-20(15)21-24-19(27)12-18(26(21)25-17)13-8-10-23-11-9-13/h1-7,12-13,23H,8-11H2,(H,24,27)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290309 ((−)-trans-10-Ethoxy-4-(2-methylpiperidin-4-y...) Show SMILES CCOc1cccc2nn3c(cc(=O)[nH]c3c12)C1CCNC(C)C1 Show InChI	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13	n/a	n/a	n/a	n/a	7.0	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...				US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290286 (7-Bromo-4-(piperidin-4-yl)pyrido[4′,3′...) Show SMILES Brc1cncc2c1nn1c(cc(=O)[nH]c21)C1CCNCC1 Show InChI InChI=1S/C14H14BrN5O/c15-10-7-17-6-9-13(10)19-20-11(5-12(21)18-14(9)20)8-1-3-16-4-2-8/h5-8,16H,1-4H2,(H,18,21)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290320 (10-Cyclopentyl-4-(piperidin-4-yl)pyrimido[1,2-b]in...) Show SMILES O=c1cc(C2CCNCC2)n2nc3cccc(C4CCCC4)c3c2[nH]1 Show InChI InChI=1S/C20H24N4O/c25-18-12-17(14-8-10-21-11-9-14)24-20(22-18)19-15(13-4-1-2-5-13)6-3-7-16(19)23-24/h3,6-7,12-14,21H,1-2,4-5,8-11H2,(H,22,25)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290324 (4-(Piperidin-4-yl)-10-[2-(trifluoromethyl)phenyl]p...) Show SMILES FC(F)(F)c1ccccc1-c1cccc2nn3c(cc(=O)[nH]c3c12)C1CCNCC1 Show InChI InChI=1S/C22H19F3N4O/c23-22(24,25)16-6-2-1-4-14(16)15-5-3-7-17-20(15)21-27-19(30)12-18(29(21)28-17)13-8-10-26-11-9-13/h1-7,12-13,26H,8-11H2,(H,27,30)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13	n/a	n/a	n/a	n/a	7.0	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...				US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290286 (7-Bromo-4-(piperidin-4-yl)pyrido[4′,3′...) Show SMILES Brc1cncc2c1nn1c(cc(=O)[nH]c21)C1CCNCC1 Show InChI InChI=1S/C14H14BrN5O/c15-10-7-17-6-9-13(10)19-20-11(5-12(21)18-14(9)20)8-1-3-16-4-2-8/h5-8,16H,1-4H2,(H,18,21)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13	n/a	n/a	n/a	n/a	7.0	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...				US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290309 ((−)-trans-10-Ethoxy-4-(2-methylpiperidin-4-y...) Show SMILES CCOc1cccc2nn3c(cc(=O)[nH]c3c12)C1CCNC(C)C1 Show InChI	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290320 (10-Cyclopentyl-4-(piperidin-4-yl)pyrimido[1,2-b]in...) Show SMILES O=c1cc(C2CCNCC2)n2nc3cccc(C4CCCC4)c3c2[nH]1 Show InChI InChI=1S/C20H24N4O/c25-18-12-17(14-8-10-21-11-9-14)24-20(22-18)19-15(13-4-1-2-5-13)6-3-7-16(19)23-24/h3,6-7,12-14,21H,1-2,4-5,8-11H2,(H,22,25)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13	n/a	n/a	n/a	n/a	7.0	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...				US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290307 ((−)-trans-10-Bromo-4-(2-methylpiperidin-4-yl...) Show SMILES CC1CC(CCN1)c1cc(=O)[nH]c2c3c(Br)cccc3nn12 Show InChI	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290329 (10-sec-Butyl-4-(piperidin-4-yl)pyrimido[1,2-b]inda...) Show SMILES CCC(C)c1cccc2nn3c(cc(=O)[nH]c3c12)C1CCNCC1 Show InChI	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	7.0	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...				US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290269 (10-Bromo-4-(piperidin-4-yl)pyrimido[1,2-b]indazol-...) Show SMILES Brc1cccc2nn3c(cc(=O)[nH]c3c12)C1CCNCC1 Show InChI InChI=1S/C15H15BrN4O/c16-10-2-1-3-11-14(10)15-18-13(21)8-12(20(15)19-11)9-4-6-17-7-5-9/h1-3,8-9,17H,4-7H2,(H,18,21)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	7.0	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...				US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290313 (10-Phenyl-4-(piperidin-4-yl)pyrimido[1,2-b]indazol...) Show SMILES O=c1cc(C2CCNCC2)n2nc3cccc(-c4ccccc4)c3c2[nH]1 Show InChI InChI=1S/C21H20N4O/c26-19-13-18(15-9-11-22-12-10-15)25-21(23-19)20-16(7-4-8-17(20)24-25)14-5-2-1-3-6-14/h1-8,13,15,22H,9-12H2,(H,23,26)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	7.0	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...				US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290312 (4-(Piperidin-4-yl)-10-[4-(trifluoromethyl)phenyl]p...) Show SMILES FC(F)(F)c1ccc(cc1)-c1cccc2nn3c(cc(=O)[nH]c3c12)C1CCNCC1 Show InChI InChI=1S/C22H19F3N4O/c23-22(24,25)15-6-4-13(5-7-15)16-2-1-3-17-20(16)21-27-19(30)12-18(29(21)28-17)14-8-10-26-11-9-14/h1-7,12,14,26H,8-11H2,(H,27,30)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	7.0	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...				US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290307 ((−)-trans-10-Bromo-4-(2-methylpiperidin-4-yl...) Show SMILES CC1CC(CCN1)c1cc(=O)[nH]c2c3c(Br)cccc3nn12 Show InChI	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	7.0	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...				US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM
					More data for this Ligand-Target Pair
Plasminogen [101-181] (Homo sapiens (Human))	BDBM290329 (10-sec-Butyl-4-(piperidin-4-yl)pyrimido[1,2-b]inda...) Show SMILES CCC(C)c1cccc2nn3c(cc(=O)[nH]c3c12)C1CCNCC1 Show InChI	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 966 total )  |  Next  |  Last  >>

Jump to: